1957年Ploug和Kje ldgaard首先成功地把尿激酶(urokinase)从人尿中分离出来,并发现具有溶解血块的能力。尔后20余年中,尿激酶在临床上得到广泛的应用,如肺血栓、深层静脉血栓、外伤性出血、动静脉分流血栓形成、植皮、断肢再植等疾病中,应用尿激酶都取得了可喜的成果。近年来,尿激酶在眼科临床的应用也日益广泛,取得了一定的成绩。现在国产尿激酶的质量已达到国际标准。一、尿激酶的生物化学特性 (一)化学特性:尿激酶是无色的水溶性蛋 In 1957 Ploug and Kjeldgaard first succeeded in isolating urokinase from human urine and found it had the ability to lyse blood clots. More than 20 years later, urokinase has been widely used clinically, such as pulmonary thrombosis, deep venous thrombosis, traumatic hemorrhage, arteriovenous shunt thrombosis, skin grafting, limb amputation and other diseases, the application of urokinase have made gratifying The result. In recent years, urokinase in the clinical application of ophthalmology is also increasingly widespread, and achieved some success. Now the quality of domestic urokinase has reached international standards. First, the biochemical characteristics of urokinase (a) chemical properties: urokinase is a colorless water-soluble egg